前收市價 | 14.85 |
開市 | 15.00 |
買盤 | 15.55 x 0 |
賣出價 | 15.60 x 0 |
今日波幅 | 14.95 - 15.00 |
52 週波幅 | 6.68 - 15.00 |
成交量 | |
平均成交量 | 296 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 2024年7月31日 - 2024年8月05日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript May 8, 2024 Teva Pharmaceutical Industries Limited misses on earnings expectations. Reported EPS is $-0.12161 EPS, expectations were $0.51. Teva Pharmaceutical Industries Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]